Ophthotech completes enrolment in Phase IIa trial of Zimura

3rd May 2018 (Last Updated May 3rd, 2018 00:00)

Ophthotech has completed patient enrolment in its Phase IIa clinical trial of Zimura (avacincaptad pegol) in combination with Lucentis (ranibizumab) for treating naïve patients with wet age-related macular degeneration (AMD).

Ophthotech completes enrolment in Phase IIa trial of Zimura
A fundus photo showing intermediate age-related macular degeneration. Credit: National Eye Institute, National Institutes of Health.

Ophthotech has completed patient enrolment in its Phase IIa clinical trial of Zimura (avacincaptad pegol) in combination with Lucentis (ranibizumab) for treating naïve patients with wet age-related macular degeneration (AMD).

AMD is a medical condition that could lead to blurred or no vision in the centre of the visual field.

The dose-ranging, multi-centre trial includes a total of 64 patients.

The trial aims to evaluate safety at different dosages and to identify a potential efficacy signal.

"Data from the trial is expected to be evaluated at month six, while initial top-line data are scheduled to be provided before the end of this year."

Data from the trial is expected to be evaluated at month six, while initial top-line data are scheduled to be provided before the end of this year.

Ophthotech chief medical officer Kourous Rezaei said: “Following the completion of this trial, clinical data will be analysed to assess whether to proceed to a randomised, sham controlled clinical trial of Zimura combination therapy in wet AMD.”

Zimura (avacincaptad pegol) was developed by Ophthotech as a complement factor C5 inhibitor for treating patients with wet AMD.

Apart from the Phase IIa, Zimura is currently being investigated as monotherapy in a Phase IIb clinical trial for patients with geographic atrophy secondary to dry AMD and in a Phase IIb clinical trial for the prevention of autosomal recessive Stargardt disease (STGD1).

Additionally, Zimura is being analysed as combination therapy with Eylea (aflibercept), an anti-VEGF agent, in patients with idiopathic polypoidal choroidal vasculopathy (IPCV).

Lucentis (ranibizumab) is an anti-vascular endothelial growth factor (anti-VEGF) agent.